Skip to main content

Table 2 Treatment-emergent adverse events through safety follow up (day 31): incidence ≥ 5% in any treatment group

From: Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator

 

Number (%) of patients

Adverse event (AE)

SC placebo + oral indomethacin

(n= 77)1

SC rilonacept + oral indomethacin

(n= 73)1

SC rilonacept + oral placebo

(n= 75)

Any AE

23 (29.9)

34 (46.6)

27 (36.0)

Discontinuations due to AE

2 (2.6)

1 (1.4)

1(1.3)

Serious AE

0

3 (4.1)

0

Headache

6 (7.8)

4 (5.5)

7 (9.3)

Dizziness

4 (5.2)

3 (4.1)

2 (2.7)

  1. 1Numbers differ from patient disposition since one patient was administered the wrong drug.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us